

MAYNE PHARMA APPPOINTS CHIEF SCIENTIFIC OFFICER

25 August 2014, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Dr Ilana Stancovski will be joining the Company as Chief Scientific Officer on 1 September 2014. Dr Stancovski will be responsible for leading Mayne Pharma's research and development operations world-wide.

Dr Stancovski has over 20 years of international experience involving positions in both the pharmaceutical industry and academia. She was previously Vice President Research & Development for Actavis Group's global Hospital Division where she made a significant contribution to expanding the company's portfolio of complex generic and long-acting injectables, including a number of potential first-to-file projects. Prior to Actavis, Dr Stancovski was the Vice President Scientific Affairs at Intas Pharmaceuticals and also held senior management roles at other multinational pharmaceutical and biotech companies.

Mayne Pharma CEO Mr Scott Richards said, "I have known Ilana for many years and she is an outstanding R&D leader who brings to Mayne Pharma a rare mix of strong generic and proprietary development expertise. She will add tremendous value to our research and development program through her experience in product development, drug delivery technologies, international regulatory affairs and project management. Execution in R&D is a vital component of Mayne Pharma's growth strategy and Ilana's depth of experience and background make her an excellent fit as we continue to expand and diversify our generic and proprietary pipelines."

Dr Stancovski holds a Ph.D. in Life Sciences from the Weizmann Institute, Israel. She also worked extensively as a post-doctoral scholar at Caltech and MIT in the United States.

For further information contact:

Scott Richards +61 8 8209 2410
Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally; either directly or through distribution partners and also provides contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

